The FDA approves the Ocular Therapeutix (NASDAQ:OCUL) sNDA for DEXTENZA to include the treatment of ocular inflammation following ophthalmic surgery as an additional indication.
DEXTENZA received FDA approval last year for ocular pain after ophthalmic surgery.
OCUL shares are up 7.8% pre-market to $4.45.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.